Images List Premium Download Classic

Prostate Cancer

Prostate Cancer-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Method for detecting or monitoring prostate cancer
Oncosense Inc. (usa)
June 22, 2017 - N°20170176443

The present invention provides methods identifying subjects having prostate cancer (pca) by detecting in microparticles a pair of biomarkers. The methods disclosed can be used to distinguish subjects having pca from those having non-malignant prostate pathologies, including benign prostatic hyperplasia. Methods for monitoring prostate cancer and assessing efficacy of prostate cancer therapies are also disclosed. Kits for detecting prostate cancer ...
NEW Methods (amacr)
University Of Bath
June 22, 2017 - N°20170176436

A method of measuring α-methylacyl-coa racemase (amacr) activity in a sample is described comprising the steps of: (i) providing a sample; (ii) contacting said sample with a substrate compound that undergoes elimination of hydrogen and a leaving group catalysed by said amacr to produce a product compound having an additional carbon-carbon double bond; and (iii) measuring the amount ...
NEW Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
The Johns Hopkins University
June 22, 2017 - N°20170175206

The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.
NEW Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof
Benevir Biopharm, Inc.
June 22, 2017 - N°20170173092

The present invention relates to exogenous tap inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade cd8+ cytolytic t-cells, and induce the immune system to recognize tumor cells. Preferred viruses of the invention have a heterologous gene that encodes a function that affects antigen presentation by inhibiting tap. The viruses of the invention also comprise one or more ...
Systems and methods for automated screening and prognosis of cancer from whole-slide biopsy images
The Board Of Regents Of The University Of Texas System
June 15, 2017 - N°20170169276

Systems and methods for detection, grading, scoring and tele-screening of cancerous lesions are described. A complete scheme for automated quantitative analysis and assessment of human and animal tissue images of several types of cancers is presented. Various aspects of the invention are directed to the detection, grading, prediction and staging of prostate cancer on serial sections/slides of prostate core ...
Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
Oy Arctic Partners Ab
June 15, 2017 - N°20170168060

Methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided. More particularly, this disclosure relates to methods and apparatuses for providing the models and employing the models for predicting risk of prostate cancer and/or predicting prostate gland volume. The methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume ...
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Biomarkers for the identification of prostate cancer and methods of use
George Washington University
June 15, 2017 - N°20170166977

The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of african american males or non-hispanic white males.
Selective androgen receptor degrader (sard) ligands and methods of use thereof
University Of Tennessee Research Foundation
June 15, 2017 - N°20170166526

This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other ar-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), abdominal aortic aneurysm (aaa), and uterine fibroids, and to ...
Predicting cancer outcome
Mayo Foundation For Medical Education And Research
June 08, 2017 - N°20170159131

This document provides methods and materials related to assessing prostate cancer in mammals. For example, this document provides nucleic acids and polypeptides that can be analyzed to determine whether a male mammal having prostate cancer is susceptible to a good or poor outcome.
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 08, 2017 - N°20170158685

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 08, 2017 - N°20170158681

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 08, 2017 - N°20170158664

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Treatment of prostate cancer
Tokai Pharmaceuticals, Inc.
June 08, 2017 - N°20170157148

Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. The present invention provides therapies and therapeutic regimens for the treatment of prostate cancer.
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Stat3 inhibitor
Board Of Regents, The University Of Texas System
June 01, 2017 - N°20170152260

Provided are stat3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e. G., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.
Phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof, preparation method ...
China Medical University
June 01, 2017 - N°20170152257

A phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof was synthesized, which exhibits potent activity as an anticancer agent against, such as breast cancer, lung cancer, and prostate cancer.
F10 inhibits growth of pc3 xenografts and enhances the effects of radiation therapy
Wake Forest University
June 01, 2017 - N°20170151240

Chemotherapy remains of limited use for the treatment of prostate cancer with only one drug, docetaxel, demonstrating a modest survival advantage for treatment of late-stage disease. Data from the nci 60 cell line screen indicated that the castration-resistant prostate cancer cell lines pc3 and du145 were more sensitive than average to the novel polymeric fluoropyrimidine (fp), f10, despite displaying less than ...
Method for predicting and treating clinically significant prostate cancer
Wake Forest University
May 25, 2017 - N°20170145518

The present invention relates to methods, devices, combinations, kits, and systems for predicting and treating clinically significant prostate cancer in a urine sample of an individual suspected of suffering from prostate cancer based on expression analysis of normalised prostate tumour markers. The present methods, devices, combinations, kits, and systems are especially suitable for predicting and treating prostate cancer with a ...
Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
Wake Forest University
May 25, 2017 - N°20170145418

The present invention provides a method for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a heat shock protein 90 (hsp90) inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject. The present invention also provides pharmaceutical compositions comprising an amount of ...
Crystalline forms and processes for the preparation of cannabinoid receptor modulators
Wake Forest University
May 25, 2017 - N°20170144993

The present invention relates to crystalline forms of (1as,5as)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((s)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor and are therefore useful in the treatment of cb2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory ...
Marmelin analogs and methods of use in cancer treatment
Wake Forest University
May 25, 2017 - N°20170144965

A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, ...
Cationic lipid cordiarimide hybrid compounds and a process for preparation thereof
Council Of Scientific & Industrial Research
May 18, 2017 - N°20170137462

The present invention relates to the cationic lipid cordiaroimide hybrid compounds of formula i. The present invention provides a process for preparation of these compounds is also being elaborated. The compounds described provides anticancerous activity against cell lines including pc-3 (prostate cancer), hepg2 (liver cancer), mcf-7 (breast cancer) and nih-1/3t3 (non cancer cells. The compound was also capable of ...
Loading